Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX

Iranian Journal of Basic Medical Sciences

Volumn 18, Issue 6, 2015, Pages 576-586

  Moosavian, Seyedeh Alia ^a   Jaafari, Mahmoud Reza ^a   Taghdisi, Seyed Mohammad ^b   Mosaffa, Fatemeh ^c   Badiee, Ali ^a   Abnous, Khalil ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Cell SELEX; RNA aptamer; TUBO cell line

Indexed keywords

EID: 84934289001     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013, 6:1-9.
2. Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y, et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 2008; 261:55-63.
3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61:1-13.
4. Pal S, Pegram M. HER2 targeted therapy in breast cancer…beyond Herceptin. Rev Endocr Metab Disord 2007; 8:269-277.
5. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008; 26:442-449.
6. Proske D, Blank M, Buhmann R, Resch A. Aptamers- -basic research, drug development, and clinical applications. Appl Microbiol Biotechnol 2005; 69:367-374.
7. Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev 2007; 107:3715-3743.
8. Cox JC, Rudolph P, Ellington AD. Automated RNA selection. Biotechnol Prog 1998; 14:845-850.
9. Farokhzad OC, Karp JM, Langer R. Nanoparticleaptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006; 3:311-324.
10. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103:6315-6320.
11. Dua P, Kim S, Lee D-k. Nucleic acid aptamers targeting cell-surface proteins. Methods 2011; 54:215-225.
12. Guo KT, Ziemer G, Paul A, Wendel HP. CELLSELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci 2008; 9:668-678.
13. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007; 24:381-403.
14. Kim Y, Liu C, Tan W. Aptamers generated by Cell SELEX for biomarker discovery. Biomark Med 2009; 3:193-202.
15. Yang Y, Yang D, Schluesener HJ, Zhang Z. Advances in SELEX and application of aptamers in the central nervous system. Biomol Eng 2007; 24:583-592.
16. Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 1999; 49:179-188.
17. Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine 2012; 8:692-701.
18. Hall B, Micheletti JM, Satya P, Ogle K, Pollard J, Ellington AD. Design, Synthesis, and Amplification of DNA Pools for In Vitro Selection. In Curr Protoc Mol Biol. Volume 9: John Wiley & Sons, Inc.; 2009: 9.2.1- 9.2.28.
19. Mayer G, Piasecki S, Hall B, Ellington A. Nucleic Acid Pool Preparation and Characterization. In: Nucleic Acid and Peptide Aptamers. Humana Press; 2009: p. 3-18: Methods in Molecular Biology.
20. Ellington A. PJ. Purification of Oligonucleotides Using Denaturing Polyacrylamide Gel Electrophoresis. In Curr: 42 Vol: John Wiley & Sons, Inc. Protoc Mol Biol\p.2.12.11-12.12.17.1998.
21. Sefah K, Shangguan D, Xiong X, O’Donoghue MB, Tan W. Development of DNA aptamers using Cell- SELEX. Nat Protoc 2010; 5:1169-1185.
22. Sioud M, Meng L, Sefah K, Colon D, Chen H, O’Donoghue M, et al. Using Live Cells to Generate Aptamers for Cancer Study. In RNA Therapeutics. Volume 629: Humana Press; 353-365: Methods in Molecular Biology.
23. http://eng.bioneer.com/home.aspx.
24. Kang HS, Huh YM, Kim S, Lee Dk. Isolation of RNA aptamers targeting HER-2-overexpressing breast cancer cells using cell-SELEX. Bull Korean Chem Soc 2009; 30:1827-1831.
25. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31:3406-3415.
26. Sefah K, Meng L, Lopez-Colon D, Jimenez E, Liu C, Tan W. DNA Aptamers as Molecular Probes for Colorectal Cancer Study. PLoS One 2010; 5:e14269.
27. Kang D, Wang J, Zhang W, Song Y, Li X, Zou Y, et al. Selection of DNA Aptamers against Glioblastoma Cells with High Affinity and Specificity. PLoS One 2012; 7:e42731.
28. Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez- Colon D, Li Y, et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009; 23:235-244.
29. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644-1646.
30. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54:16-20.
31. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000; 19:1647-1656.
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987; 235:177-182.
33. Kim MY, Jeong S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 2011; 21:173-178.
34. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 2013; 110:8170-8175.
35. Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 2012; 40:6319-6337.
36. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol Appl Biochem 2011; 58:226-230.
37. Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40:6319-6337.
38. Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, et al. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 2009; 15:924-932.
39. Ray P, White RR. Aptamers for Targeted Drug Delivery. Pharmaceuticals 2010; 3:1761-1778.
40. Germer K, Leonard M, Zhang X. RNA aptamers and their therapeutic and diagnostic applications. Int J Biochem Mol Biol 2013; 4:27-40.
41. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5:1289-1297.
42. Svoboda P, Cara AD. Hairpin RNA: a secondary structure of primary importance. Cel Mol Life Sci CMLS 2006; 63:901-908.
43. Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W. Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt’s Lymphoma Cells. Mol Cell Proteomics 2007; 6:2230-2238.
44. Jimenez E, Sefah K, Lopez-Colon D, Van Simaeys D, Chen HW, Tockman MS, et al. Generation of lung adenocarcinoma DNA aptamers for cancer studies. PLoS One 2012; 7:e46222.
45. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103:11838-11843.
46. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 2008; 7:2133-2139.
47. Tang Z, Parekh P, Turner P, Moyer RW, Tan W. Generating aptamers for recognition of virus-infected cells. Clin Chem 2009; 55:813-822.
48. Ara MN, Hyodo M, Ohga N, Hida K, Harashima H. Development of a Novel DNA Aptamer Ligand Targeting to Primary Cultured Tumor Endothelial Cells by a Cell-Based SELEX Method. PLoS One 2012; 7:e50174.